Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
This study has been terminated.
( After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible. )
Study NCT00105313   Information provided by MedImmune LLC

First Received on March 11, 2005.   Last Updated on June 12, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Leukemia
Cancer
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
MEDI-507
Sponsors listed in this trial
MedImmune LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services